Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand

Transplantation

Volumn 90, Issue 11, 2010, Pages 1165-1171

  Scott, David R ^a   Wong, Jeffrey K W ^a   Spicer, Tim S ^a   Dent, Hanna ^b   Mensah, Fiona K ^b   McDonald, Stephen ^b   Levy, Miriam T ^a  

^a LIVERPOOL HOSPITAL   (Australia)

^b Australia and New Zealand Dialysis and Transplant Registry   (Australia)

Author keywords

ANZDATA; End stage renal disease; HCV; Hepatitis C; Renal transplantation

Indexed keywords

HEPATITIS C ANTIBODY;

ADOLESCENT; ADULT; ADVERSE OUTCOME; AGED; ARTICLE; AUSTRALIA; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; DIALYSIS; FEMALE; GLOMERULONEPHRITIS; GRAFT FAILURE; GRAFT SURVIVAL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; KIDNEY TRANSPLANTATION; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; NEUROPATHY; NEW ZEALAND; OUTCOME ASSESSMENT; PATIENT IDENTIFICATION; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; SURGICAL MORTALITY;

ADOLESCENT; ADULT; AGED; AUSTRALIA; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; CHI-SQUARE DISTRIBUTION; FEMALE; GRAFT SURVIVAL; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LIVER FAILURE; MALE; MIDDLE AGED; NEOPLASMS; NEW ZEALAND; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RENAL DIALYSIS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78650307256     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181f92548     Document Type: Article

References (32)

1. Okoh EJ, Bucci JR, Simon JF, et al. HCV in patients with end-stage renal disease. Am J Gastroenterol 2008; 103: 2123.
2. Goodkin DA, Bragg-Gresham JL, Koenig KG, et al. Association of co-morbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: The dialysis outcomes and practice patterns study (DOPPS). J Am Soc Nephrol 2003; 14: 3270.
3. Gane E, Pilmore H. Management of chronic viral hepatitis before and after renal transplantation. Transplantation 2002; 74: 427.
4. Finelli L, Miller JT, Tokars JI, et al. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial 2005; 18: 52.
5. Hassan AA, Khalil R. Hepatitis C indialysis patients inEgypt: Relationship to dialysis duration, blood transfusion, and liver disease. Saudi J Kidney Dis Transplant 2000; 11: 72.
6. Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology 2002; 36: 3.
7. Hanuka N, Sikuler E, Tovbin D, et al. Hepatitis C virus infection in renal failure patients in the absence of anti-hepatitis C virus antibodies. J Viral Hepat 2002; 9: 141.
8. Locatelli F, Marcelli D, Conte F, et al. Cardiovascular disease in chronic renal failure: The challenge continues. Nephrol Dial Transplant 2000; 15(suppl 5): S69.
9. Cotler SJ, Diaz G, Gundlapalli S, et al. Characteristics of hepatitis C in renal transplant candidates. J Clin Gastroenterol 2002; 35: 191.
10. Stehman-Breen CO, Emerson S, Gretch D, et al. Risk of death among chronic dialysis patients infected with hepatitis C virus. Am J Kidney Dis 1998; 32: 629.
11. Pereira BJG, Natov SN, Bouthot BA, et al. Effectofhepatitis C infection and renal transplantation in end-stage renal disease. Kidney Int 1998; 53: 1374.
12. Espinosa M, Martin-Malo A, Alvarez de Lara MA, et al. Risk of death and liver cirrhosis in anti-HCV-positive long term haemodilaysis patients. Nephrol Dial Transplant 2001; 16: 1669.
13. Nakayama E, Akiba T, Marumo F, et al. Prognosis of anti-herpatitis C virus antibody-positive patients on regular haemodialysis therapy. J Am Soc Nephrol 2000; 11: 1896.
14. Fabrizi F, Martin P, Dixit V, et al. Meta-analysis: Effect of hepatitis C virus on mortality in dialysis. Aliment Pharmacol Ther 2004; 20: 1271.
15. Port F, Wolfe R, Mauger E, et al. Comparison of survival probabilities for dialysis vs. cadaveric renal transplant recipients. JAMA 1993; 270: 1339.
16. Fabrizi F, Lunghi G, Dixit V, et al. Meta-analysis: Anti-viral therapy of hepatitis C virus-related liver disease in renal transplant patients. Aliment Pharmacol Ther 2006; 24: 1413.
17. Mahmoud IM, Sobh MA, El-Habashi AF, et al. Interferon therapy in haemodialysis patients with chronic hepatitis C:Study of tolerance and post-transplantation course. Nephron 2005; 100: c133.
18. Breitenfeldt MK, Rasenack J, Berthold H, et al. Impact of hepatitis B and C on graft loss and mortality of patients after kidney transplantation. Clin Transplant 2002; 16: 130.
19. Einollahi B, Hajarizadeh B, Bakhtiari S, et al. Pretransplant hepatitis C virus infection and its effect on the post-transplant course of living allograft recipients. J Gastroenterol Hepatol 2003; 18: 836.
20. Roth D, Fernandez JA, Burke GW, et al. Detection of antibody to hepatitis C virus in renal transplant receipients. Transplantation 1991; 51: 396.
21. Meier-Kriesche HU, Ojo AO, Hanson JA, et al. Hepatitis C antibody status and outcomes in renal transplantation outcome. Hepatology 2001; 72: 241.
22. Huo TI, Yang WC, Wu JC, et al. Long term outcome of kidney transplantation in patients with hepatitis C virus infection. Hepatogastroen-terology 2001; 48: 169.
23. Mathurin P, Mouquet C, Poynard T, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999; 29: 257.
24. Morales JM, Dominguez-Gil B, Sanz-Guajardo D, et al. The influence of hepatitis B and hepatitis C virus infection on patient and renal graft survival. Transplant Proc 2006; 16: 130.
25. Aroldi A, Lampertico P, Montagnino G, et al. Natural history of hepatitis B and C in renal allograft recipients. Transplantation 2005; 79: 1132.
26. Pedroso S, Martins L, Fonseca I, et al. Renal transplantation in patients over 60 years of age: A single centre experience. Transplant Proc 2006; 38: 1885.
27. Alric L, Di-Martino V, Selves K, et al. Long term impact of renal transplantation on liver fibrosis during hepatitis C virus infection. Gastro-enterology 2002; 123: 1494.
28. Kamar N,Roastaing L, Selves J,et al. Natural history ofhepatitis Cvirus related liver fibrosis after renal transplantation. Am Transplant 2005; 5: 1704.
29. Disney APS. Demography and survival of patients receiving treatment for chronic renal failure in Australia and New Zealand: Report on dialysis and renal transplantation treatment from the Australia and New Zealand dialysis and transplant registry. Am J Kidney Dis 1995; 25: 165.
30. Maluf DG, Fisher RA, King AL, et al. Hepatitis C virus infection and kidney transplantation: Predictors of patient and graft survival. Transplantation 2007; 83: 853.
31. Campbell MS, Constantinescu S, Furth EE, et al. Effects of hepatitis C-induced liver fibrosis on survival in kidney transplant candidates. Dig Dis Sci 2007; 52: 2501.
32. Morales JM, Dominguez-Gil B, Sanz-Guajardo D, et al. The influence of hepatitis B and hepatitis C virus infection in the recipient on late renal allograft failure. Nephrol Dial Transplant 2004; 19: 72.